Are the screening guidelines for branch duct intraductal papillary mucinous neoplasms cost-effective in an Australian setting?
ANZ journal of surgery(2023)
摘要
This cost analysis demonstrates that screening of 2-3 cm BD-IPMN according to current guidelines is unlikely to be cost-effective in an Australian context. To determine the true ICER, a cost analysis on real-world data is required.
更多查看译文
关键词
BD-IPMN, branch duct, health economics, hepatopancreaticobiliary surgery, intraductal papillary mucinous neoplasms, IPMN
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要